PMVP news

Latest 1 stories · newest Nov 10, 2026

PMVP

PMV closes $50M offering; rezatapopt data posted for ENA 2026

PMV Pharmaceuticals reported Q3 2026 results, closing a $50 million public offering and revealing interim data showing 46% ORR for rezatapopt in ovarian cancer ahead of an NDA submission in 2027.

Offering|Other Nov 10, 2026 sentiment +0.75 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same PMVP feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/PMVP/newsSTART FREE